Vaginal atrophy across the menopausal age: results from the ANGEL study

Cagnacci, Angelo; Xholli, Anjeza; Sclauzero, Martina; Venier, Martina; Palma, Federica; Gambacciani, Marco

doi:10.1080/13697137.2018.1529748

Cited by 48 publications

(59 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Symptoms and signs of VVA occur also in younger women, prior to the menopause. An Italian study, 7 performed in a cohort of women aged between 40 and 55 years observed a prevalence of VVA and of vaginal dryness of 36.8% and of 64%, respectively.…”

Section: Introductionmentioning

confidence: 99%

<p>Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use</p>

Cagnacci¹,

Xholli²,

Venier³

2020

PPA

View full text Add to dashboard Cite

Endocrinological changes that occur with menopause lead to a chronic and progressive condition named vulvar and vaginal atrophy (VVA). This disease is characterized by symptoms such as dryness, dyspareunia, itching, burning, and dysuria. According to recent epidemiological studies, VVA has a high prevalence and can also occur in younger women prior to the menopause, negatively affecting quality of life, sexual function, intimacy and relationship with the partner. Accordingly, therapy should be effective, initiated early and continued for as long as possible. Up to recent years, available therapeutic options have included over-the-counter lubricants and moisturizers, vaginal oestrogens and systemic hormones. These products are not indicated for all women. Hormones are mostly contraindicated in women with a history of hormone-sensitive cancer and are frequently not accepted even by women without contraindications. Local therapies are frequently considered uncomfortable, difficult to apply, and messy. Indeed, these treatments have a high spontaneous discontinuation rate, mostly due to dissatisfaction, safety concern, side effects and difficulty in vaginal placement. Recently, ospemifene, a new non-hormonal systemic remedy, was approved by FDA (Food and Drug Administration) and EMA (European Medicines Agency) for the treatment of the two most bothersome symptoms of VVA: dryness and dyspareunia. Because ospemifene is a selective estrogen receptor modulator (SERM), it can be administered also in women with a history of breast cancer, and this makes it more acceptable by any woman. In addition, its route of administration minimizes those bothersome side effects intrinsic to the vaginal route of administration. Available data indicate that women using ospemifene have higher adherence to treatment, higher persistence and lower discontinuation rate. Satisfaction is higher than with other local therapies and overall health care cost is lower.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use</p>

Cagnacci¹,

Xholli²,

Venier³

2020

PPA

View full text Add to dashboard Cite

show abstract

“…Unfortunately, these complaints are often unreported as many women are uncomfortable talking to their physicians and most are unaware of possible available therapies . Symptoms and signs increase in frequency and intensity with age, and treatments should be initiated when symptoms commence and begin to cause distress . It is therefore incumbent upon physicians to inquire about these symptoms and to provide evidence‐based information about the therapeutic alternatives available.…”

Section: Introductionmentioning

confidence: 99%

“…Vulvovaginal atrophy (VVA) [1][2][3] or genitourinary syndrome of menopause (GSM) 4 affects up to 48% of pre-and between 53.8 and 90% of postmenopausal women. [5][6][7][8][9][10] Breast cancer survivors often have iatrogenic menopause, and up to 70% develop VVA/ GSM. 11 Unfortunately, these complaints are often unreported as many women are uncomfortable talking to their physicians and most are unaware of possible available therapies.…”

Section: Introductionmentioning

confidence: 99%

“…5,8,[12][13][14][15][16][17][18] Symptoms and signs increase in frequency and intensity with age, and treatments should be initiated when symptoms commence and begin to cause distress. 10,19 It is therefore incumbent upon physicians to inquire about these symptoms and to provide evidencebased information about the therapeutic alternatives available.…”

Section: Introductionmentioning

confidence: 99%

“…Vulvovaginal atrophy (VVA) or genitourinary syndrome of menopause (GSM) affects up to 48% of pre‐ and between 53.8 and 90% of postmenopausal women . Breast cancer survivors often have iatrogenic menopause, and up to 70% develop VVA/GSM .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Review of non‐invasive vulvovaginal rejuvenation

Photiou

Lin

Dubin

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Vulvovaginal atrophy (VVA) or genitourinary syndrome of menopause (GSM) may affect up to 90% of menopausal women. Features include vulvovaginal atrophy, vulvovaginal laxity, vulvovaginal dryness and irritation, dyspareunia, anorgasmia and urinary symptoms. The vulva, vagina and bladder are oestrogen‐responsive tissues, but oestrogen replacement therapy is not possible in women who have hormone‐responsive cancers or normal oestrogen levels. Therefore, there is a role for alternative treatments. To date, three non‐surgical energy‐based therapies have been proposed: fractional microablative CO2 laser, erbium:YAG laser and temperature‐controlled radiofrequency (RF). Our objective was to assess the available evidence for the safety and efficacy of erbium:YAG laser, microablative fractional CO2 laser and RF in the treatment of VVA/GSM. The authors reviewed the current published literature evaluating these therapies. All three therapies appear safe; however, all the studies were uncontrolled and used different protocols and outcome measurements. Therefore, comparison of treatments is difficult. It appears that there is more evidence in favour of the CO2 laser than the erbium:YAG laser. Both lasers have more evidence than RF. In conclusion, microablative CO2 laser, erbium:YAG laser and RF may be offered to patients suffering from VVA/GSM as an alternative or adjunct to conventional therapies. Further well‐conducted controlled studies are needed.

show abstract

Management of Genitourinary Syndrome Associated with Dyspareunia with Laser Therapy

2024

Laser Therapy in Healthcare

View full text Add to dashboard Cite

Vaginal atrophy across the menopausal age: results from the ANGEL study

Cited by 48 publications

References 23 publications

<p>Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use</p>

<p>Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use</p>

Review of non‐invasive vulvovaginal rejuvenation

Management of Genitourinary Syndrome Associated with Dyspareunia with Laser Therapy

Contact Info

Product

Resources

About